加利福尼亚州在2026年1月推出州经营的胰岛素计划 卖五包55美元 低于一般价格 California launches state-run insulin program in Jan 2026, selling 5-pack for $55, down from typical prices.

加州将于2026年1月推出州产胰岛素方案CalRx, California will launch CalRx, a state-produced insulin program, in January 2026, offering a 5-pack for $45 wholesale—far below typical pharmacy prices. 这项计划由非营利性Civica Rx和Biocon Biologics达成的5000万美元协议资助,最初是Lantus (glargine) 的通用版本,并旨在扩展到其他常见的胰岛素. The initiative, funded by a $50 million deal with nonprofit Civica Rx and Biocon Biologics, begins with a generic version of Lantus (glargine) and aims to expand to other common insulins. 州政府计划以每五包55美元的价格出售它,帮助未投保和未投保的居民。 The state plans to sell it at $55 per 5-pack, helping uninsured and underinsured residents. 此举遵循联邦胰岛素定价规则和州法律,将受保病人的胰岛素费用限制在35美元。 This move follows federal insulin pricing rules and a state law capping insulin costs at $35 for insured patients. 加利福尼亚州加入毒品制造标志着在降低处方费用方面迈出的重要一步。 California’s entry into drug manufacturing marks a major step in lowering prescription costs.